Show simple item record

dc.contributor.authorVendrik, Karuna E W
dc.contributor.authorOoijevaar, Rogier E
dc.contributor.authorde Jong, Pieter R C
dc.contributor.authorLaman, Jon D
dc.contributor.authorvan Oosten, Bob W
dc.contributor.authorvan Hilten, Jacobus J
dc.contributor.authorDucarmon, Quinten R
dc.contributor.authorKeller, Josbert J
dc.contributor.authorKuijper, Eduard J
dc.contributor.authorContarino, Maria Fiorella
dc.date.accessioned2020-05-25T19:41:32Z
dc.date.available2020-05-25T19:41:32Z
dc.date.issued2020-01-01
dc.identifier.issn2235-2988
dc.identifier.pmid32266160
dc.identifier.doi10.3389/fcimb.2020.00098
dc.identifier.urihttp://hdl.handle.net/10029/623816
dc.description.abstractBackground: Several studies suggested an important role of the gut microbiota in the pathophysiology of neurological disorders, implying that alteration of the gut microbiota might serve as a treatment strategy. Fecal microbiota transplantation (FMT) is currently the most effective gut microbiota intervention and an accepted treatment for recurrent Clostridioides difficile infections. To evaluate indications of FMT for patients with neurological disorders, we summarized the available literature on FMT. In addition, we provide suggestions for future directions. Methods: In July 2019, five main databases were searched for studies and case descriptions on FMT in neurological disorders in humans or animal models. In addition, the ClinicalTrials.gov website was consulted for registered planned and ongoing trials. Results: Of 541 identified studies, 34 were included in the analysis. Clinical trials with FMT have been performed in patients with autism spectrum disorder and showed beneficial effects on neurological symptoms. For multiple sclerosis and Parkinson's disease, several animal studies suggested a positive effect of FMT, supported by some human case reports. For epilepsy, Tourette syndrome, and diabetic neuropathy some studies suggested a beneficial effect of FMT, but evidence was restricted to case reports and limited numbers of animal studies. For stroke, Alzheimer's disease and Guillain-Barré syndrome only studies with animal models were identified. These studies suggested a potential beneficial effect of healthy donor FMT. In contrast, one study with an animal model for stroke showed increased mortality after FMT. For Guillain-Barré only one study was identified. Whether positive findings from animal studies can be confirmed in the treatment of human diseases awaits to be seen. Several trials with FMT as treatment for the above mentioned neurological disorders are planned or ongoing, as well as for amyotrophic lateral sclerosis. Conclusions: Preliminary literature suggests that FMT may be a promising treatment option for several neurological disorders. However, available evidence is still scanty and some contrasting results were observed. A limited number of studies in humans have been performed or are ongoing, while for some disorders only animal experiments have been conducted. Large double-blinded randomized controlled trials are needed to further elucidate the effect of FMT in neurological disorders.en_US
dc.language.isoenen_US
dc.subjectParkinson's diseaseen_US
dc.subjectautism spectrum disorderen_US
dc.subjectautoimmunityen_US
dc.subjectfecal microbiota transplantationen_US
dc.subjectgastrointestinal microbiomeen_US
dc.subjectgut-brain axisen_US
dc.subjectnervous system diseasesen_US
dc.subjectneurodegenerativeen_US
dc.titleFecal Microbiota Transplantation in Neurological Disorders.en_US
dc.typeArticleen_US
dc.identifier.journalFront Cell Infect Microbiol 2020; 10:98en_US
dc.source.journaltitleFrontiers in cellular and infection microbiology


This item appears in the following Collection(s)

Show simple item record